ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    Atezolizumab and daratumumab
Previous Study | Return to List | Next Study

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03023423
Recruitment Status : Active, not recruiting
First Posted : January 18, 2017
Last Update Posted : July 20, 2018
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: Atezolizumab Drug: Daratumumab Phase 1 Phase 2

Detailed Description:
This randomized (study medication assigned to participants by chance), multicenter study will provide study treatment (atezolizumab alone or atezolizumab+daratumumab) to participants with previously treated advanced or metastatic NSCLC to assess the anti-tumor activity and safety. Participants who receive atezolizumab treatment with confirmed disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be eligible to crossover to treatment (atezolizumab + daratumumab) if they meet crossover eligibility criteria. It is expected that 100 participants will enroll in the study including 6 participants in the safety run in phase. Data Monitoring Committee (DMC) will review ongoing data, and may formulate recommendations on study conduct, including expansion of enrollment of some PD-L1 subgroups, resulting in greater than 96 participants. The participants in the safety run in phase will be administered the combination of daratumumab and atezolizumab to determine the safety and tolerability that will be evaluated by the Safety Evaluation Team (SET) for dose limiting toxicity before the random assignment of participants in a 1:1 ratio in 2 treatment arms. The study consists of 3 phases: Screening Phase (up to 28 days), Treatment Phase and Post-Treatment Follow-up Phase which will continue until death, lost to follow-up, withdrawal of consent, or the End of the Study [the study end is approximately 6 to 12 months after that last participant is enrolled]. Participants will undergo tumor assessments (RECIST 1.1), immunogenicity, pharmacokinetics, biomarkers and safety evaluations (adverse events, laboratory tests, electrocardiogram [ECGs], vital sign measurements, physical examinations, Eastern Cooperative Oncology Group [ECOG] performance status score) over the time.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Actual Study Start Date : December 23, 2016
Estimated Primary Completion Date : February 28, 2019
Estimated Study Completion Date : October 14, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Arm A: Atezolizumab
Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
Drug: Atezolizumab
Participants will receive atezolizumab 1200 mg intravenously.

Experimental: Treatment Arm B: Atezolizumab and Daratumumab
Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
Drug: Atezolizumab
Participants will receive atezolizumab 1200 mg intravenously.

Drug: Daratumumab
Participants will receive daratumumab 16 mg/kg intravenously.
Other Name: JNJ-54767414




Primary Outcome Measures :
  1. Percentage of Participants With Overall Response Rate (ORR) [ Time Frame: From randomization to end of study (an expected average of 3 years) ]
    ORR is defined as the percentage of participants with partial response (PR) or complete response (CR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria for target lesions and assessed by magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), greater than or equal to (>=)30 percent (%) decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.


Secondary Outcome Measures :
  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Screening (28 days ) to end of treatment (30 days after the last dose) ]
  2. Duration of Response (DoR) [ Time Frame: From randomization to the date of first documented evidence of Progressive Disease [PD] (an expected average of 3 years ]
    Duration of Response is defined as the duration from the date of the initial documentation of a response to the date of the first objectively documented evidence of progressive disease or death (At least 20% increase in the sum of the longest diameters of index lesions), whichever status is recorded first.

  3. Percentage of Participants who Achieve Disease Control (CR, PR, or SD with duration of at least 16 weeks) Clinical Benefit Rate (CBR) [ Time Frame: From randomization to end of study (an expected average of 3 years) ]
    Clinical Benefit Rate is defined as the proportion of participants who achieve disease control (complete response [CR], Disappearance of all lesions; partial response [PR], greater than or equal to (>=) 30% decrease in the sum of the diameters of all index lesions; or stable disease [SD], less than (<) 30% decrease in sum of longest diameters of all index lesions with duration of at least 16 weeks).

  4. Progression-Free Survival (PFS) [ Time Frame: From randomization to the date of first documented evidence of PD (an expected average of 3 years) ]
    PFS is defined as the duration from the date of randomization to the date of objectively documented progression or death due to any cause, whichever status is recorded first.

  5. Overall Survival (OS) [ Time Frame: From randomization to the date of first documented evidence of PD (an expected average of 3 years) ]
    Overall Survival is defined as the duration from the date of randomization to the date of death due to any cause.

  6. Maximum Observed Analyte Concentration (Cmax) of Daratumumab [ Time Frame: Predose and end of infusion Cycle 1 Day 1(C1D1), Predose-C2D1, C3D1, C3D15, end of infusion-C3D15; predose and end of infusion-C4D1, predose and end of infusion-C8D1; predose-C12D1, C16D1 up to end of treatment (30 days after the last dose) ]
    Maximum observed analyte concentration of daratumumab will be assessed.

  7. Maximum Observed Analyte Concentration (Cmax) of Atezolizumab [ Time Frame: Predose and end of infusion-C1D1, end of infusion - C1D2, predose - C2D1, C3D1 ; pre-dose and end of infusion-C4D1, pre-dose and end of infusion-C8D1; predose-C12D1, C16D1 up to end of treatment (30 days after the last dose) ]
    Maximum observed analyte concentration of atezolizumab will be assessed.

  8. Minimum Observed Analyte Concentration (Cmin) of Daratumumab [ Time Frame: Predose and end of infusion Cycle 1 Day 1(C1D1), Predose-C2D1, C3D1, C3D15, end of infusion-C3D15; predose and end of infusion-C4D1, predose and end of infusion-C8 D1; predose-C12D1, C16D1 up to end of treatment (30 days after the last dose) ]
    Minimum observed analyte concentration of daratumumab will be assessed.

  9. Minimum Observed Analyte Concentration (Cmin) of Atezolizumab [ Time Frame: Predose and end of infusion-C1D1, end of infusion - C1D2, predose - C2D1, C3D1 ; pre-dose and end of infusion-C4D1, pre-dose and end of infusion-C8D1; predose-C12D1, C16D1 up to end of treatment (30 days after the last dose) ]
    Minimum observed analyte concentration of atezolizumab will be assessed.

  10. Anti-Daratumumab Antibodies Concentration [ Time Frame: predose - C1D1, C2D1, C8D1, C12D1, C16D1 up to end of treatment (30 days after the last dose) ]
  11. Anti-Atezolizumab Antibodies Concentration [ Time Frame: predose - C1D1, C2D1, C3D1, C4D1, C8D1, C12D1, C16D1 up to end of treatment (30 days after the last dose) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (Stage IIIb or greater)
  • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Tumor cell programmed death-ligand 1 (PD-L1) score of tumor cells (TC)1-3 and immune cell PD-L1 score of tumor-infiltrating immune cells (IC)0-3 as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained after the last line of therapy
  • A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta- hCG]) at Screening within 14 days prior to study drug administration

Inclusion Criteria for Crossover:

  • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1
  • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over. If not clinically feasible, discussion with Sponsor is required
  • The first dose of atezolizumab in the crossover arm should be within 42 days of last dose but no less than 21 days from the last dose prior to crossing over

Exclusion Criteria:

  • Received any of the following prescribed medications or therapies in the past:

    1. Anti-cluster of differentiation(CD)38 therapy, including daratumumab
    2. CD137 agonists, immune checkpoint inhibitors including but not limited to CTLA-4, anti-PD-1, and anti-PD-L1 therapies
  • Known to be seropositive for human immunodeficiency virus (HIV)
  • Prior allogeneic bone marrow transplantation or solid organ transplant
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Active hepatitis B, defined by a positive test for hepatitis B surface antigen [HBsAg] or prior history of hepatitis B, defined by presence of antibodies to hepatitis B core antigen [anti-HBc], regardless of hepatitis B surface antibody [anti-HBs] status; active hepatitis C or prior history of hepatitis C (anti-HCV positive), except in the setting of a sustained virologic response (SVR), defined as aviremia 12 weeks after completion of antiviral therapy. If hepatitis C virus (HCV) antibodies are detected, an HCV RNA test for viral load by polymerase chain reaction (PCR) should be performed at least 12 weeks after completion of antiviral therapy to rule out active infection

Exclusion Criteria for Crossover:

  • Received any subsequent anti-cancer therapies from the time between the last dose of atezolizumab prior to the first administration of study drug after crossing over
  • Whole brain radiation within 28 days or other radiotherapy within 14 days prior to first administration of study drug after crossing over

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03023423


  Hide Study Locations
Locations
United States, California
Loma Linda University
Loma Linda, California, United States, 92350
Innovative Clinical Research, Inc.
Whittier, California, United States, 90606
United States, Delaware
Christiana Care
Newark, Delaware, United States, 19713
United States, Florida
University of Miami Health System Sylvester at Deerfield Bea
Deerfield Beach, Florida, United States, 33442
Michael and Dianne Bienes Cancer Center
Fort Lauderdale, Florida, United States, 33308
Florida Hospital
Orlando, Florida, United States, 32804
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
University Cancer & Blood Center, LLC
Athens, Georgia, United States, 30607
Winship Cancer Institute Emory University
Atlanta, Georgia, United States, 30322
United States, Louisiana
Ochsner Medical Center (OMC) - New Orleans ACCRU Network Sit
New Orleans, Louisiana, United States, 70121-2429
United States, Maryland
Rcca Md, Llc
Bethesda, Maryland, United States, 20817
United States, Oklahoma
Mercy Physicians of Oklahoma
Oklahoma City, Oklahoma, United States, 73120
United States, Tennessee
Tennessee Oncology, PLLC
Chattanooga, Tennessee, United States, 37404
Tennessee Cancer Specialists
Knoxville, Tennessee, United States, 37909
Sarah Cannon Cancer Center Centenniel Medical Center
Nashville, Tennessee, United States, 37203-2173
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Washington
Medical Oncology Associates, PS
Spokane, Washington, United States, 99208-1129
France
Institut Bergonié
Bordeaux, France, 33000
Hopital Ambroise Paré - APHP Hôpitaux Universitaires Paris I - Oncologie Thoracique
Boulogne Billancourt, France, 92100
CHRU Côte de Nacre
Caen Cedex, France, 14033
Centre Hospitalier Intercommunal de Créteil
Creteil, France, 94010
Centre Hospitalier Emile Muller
Haut-Rhin, France, 68100
CHU de Montpellier - Arnaud de Villeneuve
Montpellier, France, 34295
Polyclinique de Gentilly
Nancy, France, 54000
Hôpital Européen Georges Pompidou
Paris, France, 75908
Chu Rennes - Hopital Pontchaillou
Rennes Cedex 9, France, 35033
CHU de Rouen
Rouen, France, 76031
Hopital Foch
Suresnes, France, 92151
CHU Nancy Brabois
Vandoeuvre Les Nancy, France, 54511
Germany
Charité
Berlin, Germany, 12200
Universitatsklinikum Bonn
Bonn, Germany, 53127
Klinikum Chemnitz gGmbH
Chemnitz, Germany, 913
University Hospital Dresden
Dresden, Germany, 01307
Asklepios Fachkliniken München
Gauting, Germany, 82131
LungenClinic Grosshansdorf GmbH
Großhansdorf, Germany, 22927
Asklepios Klinikum Harburg
Hamburg, Germany, 21075
Lungenklinik Hemer
Hemer, Germany, 58675
Universitätsklinikum des Saarlandes
Homburg, Germany, 66421
Universitatsklinikum Schleswig-Holstein - Lubeck
Lübeck, Germany, 23538
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany, 55131
Klinikum der Universität München
München, Germany, 80336
Hungary
National Koranyi Institute of Pulmonology and TB
Budapest, Hungary, 1121
SE Pulmonológiai Klinika
Budapest, Hungary, 1125
Orszagos Koranyi Tbc es Pulmonologiai Intezet
Budapest, Hungary, 1145
Fejer Megyei Szent Gyorgy Egyetemi Oktatokorhaz
Szekesfehervar, Hungary, 8000
Szent Borbala Hospital Tatabanya
Tatabanya, Hungary, 2800
Poland
Wojewodzki Szpital Specjalistyczny im. M. Kopernika
Lodz, Poland, 93-513
Mazowieckie Centrum Leczenia Chorob Pluc
Otwock, Poland, 05-400
Mazowiecki Szpital Onkologiczny - Oddzial Onkologiczny
Wieliszew, Poland, 05-135
Spain
Hosp. Univ. Quiron Dexeus
Barcelona, Spain, 08028
Hosp. Clinic I Provincial de Barcelona
Barcelona, Spain, 08036
Hosp. Gral. Univ. de Elche
Elche, Spain, 03203
Complejo Hospitalario de Jaen
Jaén, Spain, 23007
Hosp. Univ. Severo Ochoa
Leganés, Spain, 28911
Hosp. Univ. 12 de Octubre
Madrid, Spain, 28041
Hosp. Univ. Hm Sanchinarro
Madrid, Spain, 28050
Hosp. Gral. Univ. J.M. Morales Meseguer
Murcia, Spain, 30008
Hosp. Regional Univ. de Malaga
Málaga, Spain, 29010
Hosp. Son Llatzer
Palma De Mallorca, Spain, 07198
Hosp. Quiron Madrid Pozuelo
Pozuelo De Alarcón, Spain, 28223
Hosp. Univ. Donostia
San Sebastián, Spain, 20014
Hosp. Virgen Macarena
Sótano, Spain, Sevilla
Hosp. Clinico Univ. de Valencia
Valencia, Spain, 46010
Hosp. Arnau de Vilanova de Valencia
Valencia, Spain, 46015
Hosp. Clinico Univ. Lozano Blesa
Zaragoza, Spain, 50009
Sponsors and Collaborators
Janssen Research & Development, LLC
Genentech, Inc.
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT03023423     History of Changes
Other Study ID Numbers: CR108256
2016-002579-83 ( EudraCT Number )
54767414LUC2001 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: January 18, 2017    Key Record Dates
Last Update Posted: July 20, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Atezolizumab
Daratumumab
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs